Website Terms and Conditions
Disclosure: This website and the information contained herein is intended for use by US residents only, is provided for informational purposes only, and is not intended to replace a discussion with a health care provider. All decisions regarding patient care must be made with a health care provider and consider the unique characteristics of each patient.
Submission Guidelines: AbbVie encourages those with plaque psoriasis and their advocates to share content about their experience with moderate to severe chronic plaque psoriasis and HUMIRA (adalimumab) via the submission form on this website. This content may then be published to this web page for others to view and share. Due to the nature of the regulated industry under which this site is governed, any content submitted will be subject to the following guidelines:
By submitting content to this web page, you are releasing your content—media and text inclusive, in full or in part—for use on the HUMIRA.com website. If we would like to feature your content on any other platform, we will contact you.
AbbVie does not review, endorse, or in any way control the social media profiles/users who may share content from this page, and is not responsible for the accuracy, communication practices, or content from non-AbbVie sources.
AbbVie reserves the right not to post any content, particularly that which is considered inappropriate, off-topic, abusive, or that is used to promote and solicit for third-party sites, initiatives, or products. All content will be reviewed and may not be posted if deemed inconsistent with the intended use of this site. AbbVie reserves the right to edit or excerpt submissions in its sole discretion to ensure posted content complies with the Community Guidelines and intended use of this site.
If your submission is rejected or requires substantial edits, we may email you with the reason(s). Your privacy is important to AbbVie and there your email will not be distributed, sold, or used for any other purpose, promotional or otherwise, unless you have separately opted in to receiving emails from AbbVie.
Adverse Events (“AEs”): Any adverse events or side effects mentioned within submissions will be addressed according to FDA regulations. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.